Hemorroides

CoQ10, in combination with other antioxidants, has been shown in one study to improve respiratory function in men with obstructive sleep apnea. OSA is characterized by oxidative stress from intermittent hypoxia, and CoQ10's established antioxidant and mitochondrial protective properties are mechanistically relevant. OSA patients are at elevated cardiovascular risk—a condition in which CoQ10 supplementation has demonstrated benefit.

A cross-sectional study in 350 patients undergoing sleep studies (Journal of Clinical Sleep Medicine) found that red blood cell DHA levels were inversely related to OSA severity; each 1-SD increase in DHA was associated with approximately 50% lower odds of severe OSA after controlling for confounders. Low DHA is biologically plausible in OSA through its role in neuronal membrane function and anti-inflammatory pathways.

A clinical study in 15 patients with sleep apnea (12 obstructive, 3 central) treated with mean 2500 mg L-tryptophan at bedtime showed significant improvement in obstructive but not central sleep apnea, with the most dramatic effect in non-REM sleep. An animal study (English bulldog model of OSAHS) demonstrated that L-tryptophan combined with trazodone caused dose-dependent reductions in respiratory events in both NREM and REM sleep. The proposed mechanism involves serotonergic enhancement of upper airway dilator muscle activity.

A 2025 Mendelian Randomization study (Respiratory Medicine) confirmed a significant causal protective effect of magnesium against OSA (OR <1, p<0.05), with NHANES data showing a 64% increased likelihood of OSA in those with high magnesium depletion scores. A systematic review and meta-analysis found OSA patients had significantly lower serum magnesium levels (effect size −1.22, 95% CI: −2.24 to −0.21). Magnesium supports GABA activity, muscle relaxation, and anti-inflammatory pathways relevant to upper airway function.

Melatonin secretion is disrupted in OSA patients, with studies showing a delayed or blunted nocturnal peak. A randomized double-blind placebo-controlled trial in patients with comorbid OSA and insomnia (COMISA) demonstrated that melatonin improved sleep quality and daytime sleepiness. Research also indicates melatonin-based medications may benefit sleep quality in OSA populations with minimal adverse respiratory effects.

In a randomized placebo-controlled trial of 20 adults with obstructive sleep apnea, NAC at 600 mg three times daily for 30 days produced significant reductions in AHI, apnea-related arousals, oxygen desaturation, daytime sleepiness, and snoring, alongside reductions in oxidative stress markers. Animal models of intermittent hypoxia also show NAC mitigates oxidative stress and reduces sympathetically-driven hypertension. An ongoing Phase 3 RCT is further evaluating NAC in OSA.

Omega-3 fatty acids, particularly DHA, are inversely associated with OSA severity in cross-sectional data; each 1-SD increase in RBC DHA was associated with ~50% lower odds of severe OSA. Their anti-inflammatory properties may reduce upper airway tissue inflammation and cardiovascular risk in OSA patients. A clinical review has specifically examined omega-3 supplementation as a potential adjunct treatment for OSA and its cardiovascular complications.

Multiple meta-analyses demonstrate significantly lower serum 25(OH)D levels in OSA patients versus controls, with severity correlating inversely with vitamin D status. A 2025 multi-institutional retrospective cohort study found sustained vitamin D deficiency was associated with a 25–28% increased hazard ratio for developing OSA. Vitamin D receptors in respiratory muscles may influence upper airway dilator function and inflammatory pathways relevant to OSA.

Vitamin D3 (cholecalciferol) is the primary form studied in relation to OSA. Meta-analyses (29 studies, N=6,717) confirm lower 25(OH)D in OSA patients, with severity inversely correlated with vitamin D status. Sustained deficiency is associated with a 25–28% increased hazard for developing OSA in a large retrospective cohort. Mechanistically, vitamin D3 may support upper airway dilator muscle function and reduce OSA-associated inflammation.